Clinical Trial Update: Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating nabiximols Oromucosal Spray as add-on therapy for spasticity in people with Multiple Sclerosis has terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Nabiximols Oromucosal Spray (nabiximols)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Multiple Sclerosis (MS) | Phase 3 | Status: TERMINATED | Results posted: 2024-05-08